Why thousands of dementia sufferers are being denied the new miracle drug
In late 2022, the results of a groundbreaking stage-three trial for a ‘miracle’ new Alzheimer’s drug, lecanemab, were hailed ...
ALZFORUM2d
Lecanemab Tops Other Antibodies at Binding Soluble Aβ Aggregates
Lecanemab Favors Early Aggregates. Fluorescently labeled lecanemab (green) bound most strongly to soluble Aβ aggregates ...
Donanemab: What is the new Alzheimer’s drug rejected by the NHS?
Donanemab: What is the new Alzheimer’s drug rejected by the NHS? - Donanemab and another new drug for Alzheimer’s called ...
Lifetime Achievement Award, Lecanemab And Biomarkers In Focus At CTAD
Lecanemab is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...
The American Journal of Managed Care10d
Discarded Lecanemab Leads to Medicare Drug Waste of Up to $336 Million
Lecanemab (Leqembi; Eisai/Biogen) received traditional approval from the FDA in July 2023, following an accelerated approval ...
Monthly Prescribing Reference2d
Annual Wasteful Spending on Lecanemab Estimated at $133 to $336 Million
HealthDay News — Annual wasteful spending on discarded lecanemab is anticipated to range between $133 and $336 million, given current vial sizes, according to a research letter published online ...
openaccessgovernment1d
Donanemab: NHS rejects second promising drug for Alzheimer’s
A second groundbreaking drug (donanemab) for Alzheimer's disease has been rejected for widespread use by the NHS in England ...
Science Daily9d
Smaller vial size for Alzheimer's drug could save Medicare hundreds of millions per year
Medicare could save up to 74% of the money lost from discarded Alzheimer's drug lecanemab by the simple introduction of a new vial size that would reduce the amount of unused medication that is thrown ...
Eisai Will Request Reconsideration Of Initial Decision For Lecanemab In Australia
Eisai will request a reconsideration of this initial decision under Section 60 of the Therapeutic Goods Act within 90 days to make lecanemab available for eligible people living with early AD in ...
Armed robbery in Revesby8d
TGA's Decision To Not Register Lecanemab
The Therapeutic Goods Administration (TGA) has made the decision not to register lecanemab (LEQEMBI) for the treatment of patients with Mild Cognitive ...
Morningstar8d
Eisai will request reconsideration of initial decision for lecanemab in Australia
Eisai will request a reconsideration of this initial decision under Section 60 of the Therapeutic Goods Act within 90 days to make lecanemab available for eligible people living with early AD in ...
Yahoo Finance7d
Eisai will request reconsideration of initial decision for lecanemab in Australia
STOCKHOLM, Oct. 16, 2024 /PRNewswire/ --BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia issued a public ...